Maiche A G
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Anticancer Drugs. 1994 Jun;5(3):305-8. doi: 10.1097/00001813-199406000-00007.
Peritoneal effusion is a common complication in disseminated cancer. Intracavitary instillation of various agents has achieved control rates of 30-60% with no rational preference for one agent or another. However, serious side effects have also been observed and deaths due, for instance, to bleomycin have been reported. Mitoxantrone has recently been tested to treat effusions, and preliminary results suggest the high efficacy of this drug in the treatment of peritoneal, pericardial and pleural effusions. Nevertheless, some results have been conflicting. In the present study, 41 patients with peritoneal effusions were treated with intracavitary bleomycin or intracavitary mitoxantrone. The median duration of control of effusion was 5 months (range 1 week to 14 months) with mitoxantrone and 4 months (range 1 week to 12 months) with bleomycin. We conclude that, taking into account their limitations, both agents can be used successfully in the treatment of peritoneal effusions.
腹腔积液是播散性癌症的常见并发症。腔内注入各种药物的控制率为30%至60%,但对任何一种药物都没有合理的偏好。然而,也观察到了严重的副作用,例如,有因博来霉素导致死亡的报道。米托蒽醌最近被用于治疗积液的试验,初步结果表明该药物在治疗腹腔、心包和胸腔积液方面具有高效性。然而,一些结果相互矛盾。在本研究中,41例腹腔积液患者接受了腔内博来霉素或腔内米托蒽醌治疗。米托蒽醌组积液控制的中位持续时间为5个月(范围1周-14个月),博来霉素组为4个月(范围1周-12个月)。我们得出结论,考虑到它们的局限性,两种药物均可成功用于治疗腹腔积液。